Skip to main content
xMedica

NCT07636590ClinicalTrials.gov

Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

A Multi-Center, Prospective, Non-Interventional Study in Subjects With Limbal Stem Cell Deficiency

RecruitingTaking participants now, according to the registry record.
Contact this study

In brief

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Observational500 participants sought21 sites1 country

Categories

Registered in 1 registry

One study can be registered in several registries. We show it once and link every record we hold.

Trial information is shown as published by the registry, in its original language.

Interested in this study?

Sign in or create an account to register your interest and follow this study.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Not stated: Registered after enrolment began (about 18 days after the recorded start)First posted 2026-06-09; recorded start 2026-05-22
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Not stated: Whether participants are randomly assigned is not stated in the registry recordNo allocation method is recorded
  • Not stated: A comparison group is not stated in the registry recordThe record describes a single study arm
  • Not stated: Whether the study is blinded is not stated in the registry recordNo masking information is recorded
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 2 other studies in this databaseCounted from the lead sponsor named in the record (Claris Biotherapeutics, Inc.)
  • Not stated: No posted results from this sponsor are in this database yetBased on the sponsor’s studies in this database
  • The record lists 1 condition.
  • Lead sponsor type recorded as: industry.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourEXPLORATORY

An exploratory-stage design for a study of this type, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation0/20

    Allocation not stated in the record

  • Blinding0/20

    Masking not stated in the record

  • Control arm0/15

    No comparator arm stated in the record

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre5/8

    Multi-centre: 2 sites

  • Data monitoring committee0/7

    No data monitoring committee stated

  • Prospective registration3/5

    Registered within 30 days of the study start

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study: 500 participants (target), run at 21 sites.

How this score is built
  • Enrolment26/40

    500 participants (target)

  • Site count4/25

    2 sites

  • Country count0/15

    Single country

  • Planned duration7/10

    Planned over about 22 months

  • Sponsor scale1/10

    Claris Biotherapeutics, Inc. has led 3 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Summary

The goal of this non-interventional, observational study is to describe the natural history, clinical course, and management patterns of subjects with limbal stem cell deficiency (LSCD).

Conditions

  • Limbal Stem Cell Deficiency

Eligibility

Eligibility
SexAll
Ages12 Years – 99 Years
Healthy volunteersNo
Sampling methodPROBABILITY_SAMPLE

Study population

Adult and adolescent subjects with qualifying LSCD

Eligibility as written in the registry

Inclusion Criteria: * A photopic BCVA in the prospective study eye(s) of ≤ 70 letters at the Screening and Day 1 visits AND a change of ≤ 10 letters in photopic BCVA at Day 1 compared to the Screening Visit * Qualifying LSCD diagnosis in the study eye(s) prior to enrollment at Day 1 * Written confirmation that exclusions on retinal findings are met in the study eye(s) prior to enrollment at Day 1 * Inflammation associated with LSCD or other non-infectious inflammation (e.g., dry eye, ocular rosacea, and blepharitis) that will not interfere with the subject's participation in the opinion of the investigator is permitted. Exclusion Criteria: * Any active ocular infection in either eye at either the Screening or Day 1 visits * Active sterile iritis or uveitis in either eye at Screening or Day 1 visits * Screening visit retinal exam finding, in the opinion of the investigator, that would limit potential for visual acuity gain in the study eye(s) Note: Other inclusion/exclusion criteria apply.

Eligibility in plain statements

This record's criteria have not been broken into separate statements yet. The registry text above is complete and is the authoritative version.

Study design

Study design
Study typeObservational
PhaseNot stated in the registry record
AllocationNot stated in the registry record
Intervention modelNot stated in the registry record
Primary purposeNot stated in the registry record
MaskingNot stated in the registry record
Enrolment500 participants sought

Sponsor and collaborators

  • Claris Biotherapeutics, Inc. Sponsor

Arms and interventions

  • Non-interventional

    No product administration.

Interventions

  • Other Non-interventional

    Non-interventional

Outcome measures

  1. Primary outcome

    Natural Progression of LSCD as Assessed by Changes in Patient Reported Outcomes

    Onset or changes (worsening or improving) in vision-related quality of life and ocular symptoms as captured with the National Eye Institute Visual Function Questionnaire-25 (VFQ-25) and Ocular Surface Disease Index (OSDI) questionnaires

    Time frame Screening through Week 84

  2. Primary outcome

    Natural Progression of LSCD as Assessed by Functional Changes (Photophobic BCVA)

    Change in photophobic BCVA

    Time frame Screening through Week 84

  3. Primary outcome

    Natural Progression of LSCD as Assessed by Functional Changes (Low-luminance BCVA)

    Change in low-luminance BCVA

    Time frame Screening through Week 84

  4. Primary outcome

    Natural Progression of LSCD as Assessed by Functional Changes (Low-contrast BCVA)

    Change in low-contrast BCVA

    Time frame Screening through Week 84

  5. Primary outcome

    Natural Progression of LSCD as Assessed by Functional Changes (Contrast Sensitivity)

    Change in contrast sensitivity (Pelli-Robson)

    Time frame Screening through Week 84

  6. Primary outcome

    Natural Progression of LSCD as Assessed by Anatomical/Structural Changes

    Change in area of central cornea conjunctivalization

    Time frame Screening through Week 84

  7. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Functional Changes (Corneal Sensitivity)

    Changes (onset, improvement, or worsening) in corneal sensitivity

    Time frame Screening through Week 84

  8. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Corneal Topography/Tomography)

    Changes (onset, improvement, or worsening) in corneal topography and/or tomography and/or densitometry

    Time frame Screening through Week 84

  9. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial Defect Frequency)

    Changes (onset, improvement, or worsening) in epithelial defect frequency

    Time frame Screening through Week 84

  10. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Palisades of Vogt Crypts)

    Changes (onset, improvement, or worsening) in Palisades of Vogt crypts

    Time frame Screening through Week 84

  11. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Epithelial and Total Corneal Thickness)

    Changes (onset, improvement, or worsening) in epithelial and total corneal thickness

    Time frame Screening through Week 84

  12. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Anatomical Changes (Pannus)

    Changes (onset, improvement, or worsening) in pannus

    Time frame Screening through Week 84

  13. Secondary outcome

    Changes that May be Correlated with LSCD as Assessed by Changes Ocular and Systemic Health Outcome Measures

    Changes (onset, improvement/resolution, or worsening) of an existing condition

    Time frame Screening through Week 84

Dates

Dates
Start dateMay 22, 2026 (actual)
Primary completionMarch 1, 2028 (estimated)
CompletionMarch 1, 2028 (estimated)
First postedJune 9, 2026 (actual)
Last updatedNovember 18, 2026
Results postedNot stated in the registry record
Status last verifiedNovember 2026

Actual means the event happened. Estimated means the sponsor expects it. The two mean different things.

Locations

21 sites are recruiting

United States

United States
FacilityCityState or regionStatus
Claris Investigative SiteCarmelIndianaRecruiting
Claris Investigative SiteCranberry TownshipPennsylvaniaRecruiting
Claris Investigative SiteDraperUtahRecruiting
Claris Investigative SiteHuntington BeachCaliforniaRecruiting
Claris Investigative SiteIndianapolisIndianaRecruiting
Claris Investigative SiteKansas CityMissouriRecruiting
Claris Investigative SiteLa JollaCaliforniaRecruiting
Claris Investigative SiteLos AngelesCaliforniaRecruiting
Claris Investigative SiteLouisvilleKentuckyRecruiting
Claris Investigative SiteMinnetonkaMinnesotaRecruiting
Claris Investigative SiteNorfolkVirginiaRecruiting
Claris Investigative SiteOverland ParkKansasRecruiting
Claris Investigative SitePalisades ParkNew JerseyRecruiting
Claris Investigative SitePortlandOregonRecruiting
Claris Investigative SiteRockville CentreNew YorkRecruiting
Claris Investigative SiteSan AntonioTexasRecruiting
Claris Investigative SiteSioux FallsSouth DakotaRecruiting
Claris Investigative SiteSmyrnaTennesseeRecruiting
Claris Investigative SiteSouth DartmouthMassachusettsRecruiting
Claris Investigative SiteTampaFloridaRecruiting
Claris Investigative SiteWichitaKansasRecruiting

Study documents

No documents are linked in this registry record.

Changes over time

  1. November 18, 2026

    Site added

    13 sites added (21 total)

    821

  2. August 6, 2026

    Site added

    6 sites added (8 total)

    28